A pilot study: (131)I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically created resection cavity (SCRC) to achieve a...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Reardon, David A., Zalutsky, Michael R., Akabani, Gamal, Coleman, R. Edward, Friedman, Allan H., Herndon, James E., McLendon, Roger E., Pegram, Charles N., Quinn, Jennifer A., Rich, Jeremy N., Vredenburgh, James J., Desjardins, Annick, Guruangan, Sridharan, Boulton, Susan, Raynor, Renee H., Dowell, Jeanette M., Wong, Terence Z., Zhao, Xiao-Guang, Friedman, Henry S., Bigner, Darell D.
Формат: Artigo
Язык:Inglês
Опубликовано: Duke University Press 2008
Предметы:
Clinical Investigations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2613820/
https://ncbi.nlm.nih.gov/pubmed/18287339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2007-053
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы